USFDA Grants Approval for Contract Manufacturing Line 3 at Jubilant Pharmova Subsidiary in U.S.A.

USFDA Grants Approval for Contract Manufacturing Line 3 at Jubilant Pharmova Subsidiary in U.S.A.​

Jubilant Pharmova Limited has announced that the U.S. Food and Drug Administration (USFDA) has granted approval for commercial batch manufacturing of its first product on Line 3 of the contract manufacturing facility located in Spokane, Washington, U.S.A.

The approval pertains to the new Isolator based fill and finish line at Jubilant HollisterStier LLC's facility. This facility is part of a corporate structure where Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which in turn is a subsidiary of Jubilant Pharmova Limited, Singapore, a wholly owned entity of the parent company.

Jubilant HollisterStier operates as an integrated contract manufacturer providing specialized manufacturing services for both the pharmaceutical and biopharmaceutical industries. The facility handles sterile injectables (liquid and lyophilization) and ophthalmics (Ointment, liquid and creams), offering support ranging from process qualifications through commercial release.

Global Operations of Jubilant Pharmova Limited​

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating across several key business areas including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectables, Contract Research Development and Manufacturing, Generics, and Proprietary Novel Drugs. The Company operates globally with a workforce of approximately 5,500 multicultural people.

Key aspects of the company's global operations include:

• Radiopharma: The Radiopharma business involves manufacturing and supply of radiopharmaceutical products and services, supported by a network of 45 radiopharmacies in the USA.
• Allergy Immunotherapy: This business focuses on the manufacture and supply of allergic extracts and venom products across various markets including Canada, Europe, and Australia.
• Contract Development and Manufacturing (CDM): The CDM segment utilizes facilities in Spokane, U.S.A., and Montreal, Canada, providing end-to-end solutions such as sterile fill-and-finish injectables and comprehensive ophthalmic products.
• Research and Manufacturing: Contract Research Development and Manufacturing services are delivered through three world class research centers (two in India and one in France), alongside a US FDA approved Active Pharmaceutical Ingredients manufacturing facility located in Nanjangud, Karnataka.
• Generics and Proprietary Novel Drugs: The Generics business focuses on the development, manufacturing, and distribution of Solid Dosage Formulations while Proprietary Novel Drugs focuses on innovative biopharmaceutical therapies for oncology and auto-immune disorders.

Jubilant Pharmova Limited maintains a commitment to delivering value to its customers spread across over 75 countries, establishing itself as a 'Partner of Choice' globally.

JUBLPHARMA Stock Price Movement​

On Friday, Jubilant Pharmova Limited settled at ₹880.35, edging higher by 0.68% in the markets close after gaining ₹5.95. The stock saw brisk trading, with 229,193 shares transacting during the session.